1.0/14

June 16, 2014 (updated)

Dr. Margaret Chan
Director General
World Health Organization
Geneva

Dear Dr. Chan,

We, the 129 signatories to this letter, are writing to express our support for WHO's evidence-based approach to determine the best way forward for public health to respond to Electronic Nicotine Delivery Systems (ENDS), as expressed in WHO's June 3, 2014 statement.<sup>1</sup>

Recently, media attention was focused on a statement by a group of "specialists in nicotine science and public health policy." Unfortunately, the statement makes several assertions about ENDS' marketing, emissions, harms, and use that are either contradicted by available evidence or for which no evidence is currently available. (Indeed, the statement does not cite a single scientific study.)

The statement also included several policy recommendations, including effectively exempting ENDS from FCTC Articles 8 and 13 and ignoring Article 5.3.

It is fundamental that WHO and other public health authorities not buy into the tobacco industry's well-documented strategy of presenting itself as a "partner." If the tobacco industry was committed to reducing the harm caused by tobacco use, it would announce target dates to stop manufacturing, marketing and selling its "more harmful" products rather than simply adding e-cigarettes to its product mix and rapidly taking over the e-cigarette market. It would also immediately desist from its aggressive opposition to tobacco control policies such as tax increases, graphic health warnings and plain packaging.

By moving into the e-cigarette market, the tobacco industry is only maintaining its predatory practices and increasing profits. As stated in the guidelines for Article 5.3 of the WHO FCTC, there is a "fundamental and irreconcilable conflict of interest" between the tobacco industry's interests and public health's interests."

Public health embraced cigarette filters and "low tar" cigarettes as harm reduction strategies before manufacturers provided evidence and at a time when the manufacturers were well aware that these technologies did not actually reduce harm but were designed to promote cigarette sales by reassuring a concerned public that the new products were safer. The negative consequences of these acts remain in cancer and heart disease hospital wards throughout the world. Ignoring the link between ENDS and the tobacco industry is overlooking

the WHO FCTC Parties' legal obligation to protect government policies against tobacco industry interference.

The aggressive marketing and promotion of e-cigarettes to youth is well-documented <sup>9-10-11-12</sup> and evidence from the US<sup>13-14</sup> and Korea<sup>15</sup> shows rapid growth in youth e-cigarette use, including disturbing rates among youth who have never smoked a cigarette. One e-cigarette manufacturer warns parents that "kids may be particularly vulnerable" to the flavoring in its products. <sup>16</sup>

Manufacturers of ENDS are making a range of false and unproven claims, <sup>17-18-19</sup> misleading the public into thinking these products are harmless (they are not) and effective cessation aids (unknown). Most ENDS users are "dual users" who continue to smoke cigarettes. <sup>20</sup> Reviews of evidence about reducing smoking (instead of quitting) show that dual users are unlikely to see any health benefit in terms of cardiovascular disease. <sup>21</sup>-<sup>22</sup> Population studies of all smokers consistently show that smokers who use ENDS are *less* likely to stop smoking. <sup>23-24-25-26-27-28</sup>

The evidence is insufficient to accept the assertions that ENDS are effective as a smoking cessation device. There is a single randomized controlled trial of early generation e-cigarettes that found no difference between ENDS delivered directly to experimental subjects compared with mailing subjects a voucher that they could take to a pharmacy to obtain nicotine replacement therapy. <sup>29</sup> One population-based cross-sectional study found that highly motivated smokers using ENDS to quit were less likely to be still smoking than smokers making unassisted quit attempts with over-the-counter NRT. <sup>30</sup> However, this cross-sectional study <sup>31</sup> showed a point prevalence of 80% of smokers using ENDS in a cessation attempt having failed, compared to 84.6% of those who tried to quit unassisted. Significantly, the former study is biased against conventional therapy (because of the additional barrier to getting the NRT) and the latter did not report a comparison with well-supervised approved cessation therapies.

There is already good evidence that ENDS emissions release several toxic substances into the environment that cause harm to health. These substances include ultrafine particles, propylene glycol, tobacco-specific nitrosamines; nicotine; volatile organic compounds (VOCs), and carcinogens and reproductive toxins, including benzene, lead, nickel, and others. 32-33-34-35-36-37-38-39-40 Proposals to allow ENDS use in indoor spaces like workplaces, bars and transportation could see significant exposure to these substances.

It is important to note that nicotine itself is not harmless, which is why strict regulatory measures are in place to control the marketing of Nicotine Replacement Therapy for smoking cessation. The 2014 U.S. Surgeon General Report includes an extensive review of acute and long-term effects of nicotine exposure. It concludes, among other things, that nicotine exposure has adverse effects on fetal growth and development, including fetal brain development. The manufacturer of one electronic cigarette in the U.S. acknowledges in its product labeling that nicotine is not harmless. Acute poisoning from nicotine is well established, and there has been an increase in documented cases of children being accidentally poisoned by ingesting the liquid content of ENDS cartridges.

Remaining unregulated, risk profiles and potential harms these products may pose to the public are unknown. The absence of detailed evidence on adverse health effects is not evidence that no effect exists. Rather, insufficient time has elapsed to determine what effects exist and their magnitude on a population level.

Manufacturers have not secured regulatory approval for claims that ENDS are effective products for smoking cessation or harm reduction from regulatory authorities in any country. From a population perspective, it is important to know what new risks a consumer product may introduce in the market.

We applaud WHO's commitment to listen to the experience from Member States that have successfully implemented tobacco control and regulated sales, marketing and use of ENDS. Implementation of the WHO FCTC by its 178 parties demonstrates great progress in decreasing the harm caused by tobacco use and decreasing the burden from NCDs.

There is evidence of success from many countries, including Australia, Brazil and Turkey. The former prohibits import and sales of cartridges containing nicotine, the latter two banned import, sales and marketing of e-cigarettes until, and unless, manufacturers present safety information.

Both scientific evidence and best practices are available to support a regulatory framework that will best prevent initiation of use among youth and other non-tobacco users, protect bystanders in public areas from involuntary exposure, regulate marketing, and prohibit unsubstantiated claims.

Such a regulatory framework would require manufacturers to present safety and efficacy data. In this case, the use of these products as cessation aids (if the evidence supports such use) would operate under the supervision of a health authority that could control manufacturers' claims, impose health warnings about risks, require disclosure of ingredients and safety data and regulate product engineering as well as mandate surveillance.

This is the path that the WHO has been pursuing and encouraging. We urge you to continue doing so.

## Professor Özdemir Aktan

President
Turkish Medical Association

### **Professor Kristina Alexanderson**

Stockholm Sweden

#### Peter Allebeck

Professor of Social Medicine
Department of Public Health Sciences
Karolinska Institute
Stockholm
Sweden

### Alberto Jose de Araujo MD, PhD

Nucleus of Research on Tobacco Treatment Thorax Diseases Institute Federal University of Rio de Janeiro Brazil

## Dr. Monika Arora PhD, MSc (PH), MSc (CD)

Director, Health Promotion &
Adjunct Associate Professor
Public Health Foundation of India &
Executive Director
HRIDAY (Health Related Information Dissemination Amongst Youth)
India

### Carlos M. Artundo MD

Director EASP, Andalusian School of Public Health Spain

#### **Professor John Ashton CBE**

President, UK Faculty of Public Health United Kingdom

### **Dr Ozen Asut**

Associate Professor of Public Health
Former President of the Turkish Medical Association
Former member of Hacettepe University Medical Faculty
Editor, "Continuing Medical Education Journal" of the Turkish Medical Association
Turkey

#### **Professor Rifat Atun**

Professor of Global Health Systems
Director, Global Health Systems Cluster
Department of Global Health and Population
Harvard School of Public Health
Harvard University
USA

### Dileep G Bal MD MS MPH

Founder/Director of California's Tobacco Control Program (1981 to 2005)
Former American Cancer Society President (2000-2001)
Kauai District Health Officer,
Special Advisor to the Director on Tobacco and Chronic Disease,
Hawai'i State Department of Health.
Clinical Professor, Hawai'i Cancer Center and College of Medicine,
University of Hawaii
USA

### **Robert L Balster PhD**

Butler Professor of Pharmacology and Toxicology Research Professor of Psychology and Psychiatry Co-Director, Center for the Study of Tobacco Products Virginia Commonwealth University Richmond, VA USA

## Joaquin Barnoya MD

Research Director Unidad de Cirugia Cardiovascular de Guatemala Guatemala

#### **Robert Beaglehole MD**

Professor Emeritus University of Auckland Chair, Lancet NCD Action Group New Zealand

### Jay E Berkelhamer MD FAAP

Adjunct Professor of Pediatrics, Emory University School of Medicine Adjunct Clinical Professor of Pediatrics Morehouse College of Medicine Past President (2006-2007) American Academy of Pediatrics USA

### **Dr Mitchel Blair**

Officer for Health Promotion Royal College of Paediatrics and Child Health United Kingdom

## Ruth Bonita MPH PhD MD (hon)

Emeritus Professor University of Auckland New Zealand

#### **Helmut Brand**

Jean Monnet Professor in European Public Health
Head of the Department of International Health
President EHFG (European Health Forum Gastein)
Past President ASPHER (Association of Schools of Public Health in the European Region)
Maastricht University
The Netherlands

#### **Professor Sir Harry Burns**

Prof of Global Health
University of Strathclyde
Former Scottish Chief Medical Officer
United Kingdom

### **Professor Reinhard Busse**

Technical University Berlin Germany

### Simon Capewell MD DSc

Professor of Clinical Epidemiology
University of Liverpool
Department of Public Health & Policy,
Institute of Psychology, Health & Society.
United Kingdom

## **Dr Hilary Cass**

President
Royal College of Paediatrics and Child Health
United Kingdom

#### Frank J Chaloupka PhD

Distinguished Professor of Economics and Public Health Director, Health Policy Center University of Illinois at Chicago USA

## Simon Chapman AO PhD FASSA HonFFPH (UK)

Professor Sydney School of Public Health University of Sydney Emeritus Editor, Tobacco Control Australia

# Prof Luke Clancy BSc MB MD PhD FRCPI FRCP (Edin) FFOMRCPI

Director General TobaccoFree Research Institute Ireland

### **Peter Cooper MD**

Professor and Head Department of Paediatrics

University of the Witwatersrand & Charlotte Maxeke Johannesburg Academic Hospital Treasurer and Member of Executive Committee, International Pediatric Association South Africa

#### Professor Elif Dagli

Pediatric Pulmonologist, Turkey Chair, Health Institute Association, Turkey Chair, Pediatric Pulmonology Society, Turkey Past Chair, National Coalition on Tobacco or Health Turkey

#### **Professor Mike Daube AO**

Professor of Health Policy and Director, Public Health Advocacy Institute Curtin University, Perth President, Australian Council on Smoking and Health Australia

### Sean P David MD SM DPhil

Clinical Associate Professor of Family & Community Medicine Division of General Medical Disciplines Stanford University School of Medicine USA

#### Marisa de Andrade PhD

Impact Research Fellow Stirling Management School Institute for Social Marketing University of Stirling United Kingdom

### **Pascal Diethelm MSc**

President, OxyRomandie Geneva Switzerland

#### **Peter Donnelly MD**

Professor of Public Health Medicine University of St Andrews Former Deputy Chief Medical Officer, Scottish Government United Kingdom

# Richard Edwards MB BChir, MRCP, FCPHM(NZ), MPH, MD

University of Otago New Zealand

### **Thomas Eissenberg PhD**

Professor of Psychology and Co-director Center for the Study of Tobacco Products Virginia Commonwealth University USA

#### Esteve Fernández MD PhD

Head, Tobacco Control Unit, Catalan Institute of Oncology/ Bellvitge Institute of Biomedical Research - ICO-IDIBELL
Associate Professor of Epidemiology and Public Health, University of Barcelona
Spain

### Valeska C Figueiredo MD PhD

Center for Studies on Tobacco and Health National School of Public Health Fiocruz Foundation Brazil

### Sharon Fonn MBBCh DOH DEpi FFCH PhD MASSAf

Professor

School of Public Health, University of the Witwatersrand, Johannesburg Co-director Consortium for Advanced Research Training in Africa Vice President Association of Schools of Public Health in Africa South Africa

## **Becky Freeman PhD**

Research Fellow School of Public Health University of Sydney Australia

## Karine Gallopel-Morvan PhD

Professeure des Universités - Marketing social Professor - Social marketing Equipe de recherche Management des Organisations de Santé (MOS) Institut du Management Rennes France

#### Stanton A Glantz PhD

**Professor of Medicine** 

American Legacy Foundation Distinguished Professor of Tobacco Control Director, Center for Tobacco Control Research and Education Director, WHO Collaborating Centre on Tobacco Control University of California, San Francisco USA

## **Professor Dr Helmut Gohike MD FESC FACC**

Chairman of the taskforce of cardiovascular prevention German Cardiac Society Ballrechten/Dottingen Germany

## **Mark Gottlieb**

Executive Director
Public Health Advocacy Institute
at Northeastern University School of Law
Boston MA
USA

## Prakash C Gupta

Director Healis - Sekhsaria Institute for Public Health India

### Sir Andy Haines MD

Professor of Public Health and Primary Care London School Of Hygiene & Tropical Medicine United Kingdom

## Bonnie Halpern-Felsher PhD FSAHM

Professor of Pediatrics
Director of Research
Associate Director, Adolescent Medicine Fellowship Program
Division of Adolescent Medicine, Department of Pediatrics
Stanford University
USA

## **Professor Gerard Hastings OBE**

The Institute for Social Marketing
University of Stirling, the Open University and
L'École des Hautes Etudes en Santé Publique
Stirling
United Kingdom

## **Professor Dr Reiner Hanewinkel**

Director Institute for Therapy and Health Research, Kiel Germany

### **Todd Harper**

Chief Executive Officer Cancer Council Victoria Australia

### Norbert Hirschhorn MD

In-Kind Consultant, Faculty of Health Sciences Tobacco Control Research Group American University of Beirut Lebanon

### Janet Hoek PhD

University of Otago New Zealand

## Winthrop Professor C. D'Arcy J Holman AM

Chair in Public Health School of Population Health University of Western Australia Australia

### Dr Zulkifli Ismail MD

President, Asia Pacific Pediatric Association (APPA)
Past President, Malaysian Paediatric Association (MPA)
Malaysia

## Robert K Jackler, MD

Sewall Professor and Chair
Otolaryngology-Head & Neck Surgery
Director, Stanford Research Into the Impact of Tobacco Advertising
Stanford University School of Medicine
USA

### **Professor Staffan Janson MD**

Department of Public Health Karlstad University Karlstad Sweden

# William J Keenan, MD

Executive Director
International Pediatric Association
USA

## Jonathan D Klein MD MPH FAAP

Director, Secretariat, NCD Child Chair, Technical Assistance Group on NCDs, International Pediatric Association Associate Executive Director, American Academy of Pediatrics USA

### J Randy Koch PhD

Executive Director
Institute for Drug and Alcohol Studies
Assoc. Professor, Family Medicine and Population Health
Virginia Commonwealth University
Richmond, VA
USA

### **Prof Andreas Konstantopoulos MD**

President, International Pediatric Association (IPA)
Greece

#### Colleen A Kraft MD FAAP

Professor of Pediatrics
Virginia Tech Carilion School of Medicine and Research Institute
Chair of the Richmond Center Advisory Committee
USA

## Professor Dr M Tezer Kutluk, MD PhD

Department of Pediatrics, Division of Pediatric Oncology
Hacettepe University Faculty of Medicine & Cancer Institute
President, National Coalition on Tobacco or Health, Turkey
Immediate Past President, European Cancer Leagues, Brussels
Past President, Turkish Association for Cancer Research and Control
Turkey

### Professor Dr med Ulrich Laaser DTM&H MPH

Section of International Public Health (S-IPH)
Faculty of Health Sciences
University of Bielefeld
Germany

## **Dr Gabrielle Laing**

Chair British Association for Community Child Health United Kingdom

## Harry A Lando PhD

Distinguished International Professor University of Minnesota USA

#### **Professor Stephen Leeder AO**

Emeritus Professor of Public Health and Community Medicine Menzies Centre for Health Policy and School of Public Health University of Sydney Editor-in-Chief, Medical Journal of Australia Australia

#### Simon Lenton

Co-Chair
British Association of Child and Adolescent Public Health (BACAPH)
United Kingdom

### **Professor Alastair H Leyland**

Associate Director
MRC/CSO Social and Public Health Sciences Unit
University of Glasgow
United Kingdom

### Pamela Ling MD MPH

Associate Professor of Medicine Associate Director, Center for Tobacco Control Research and Education University of California San Francisco USA

## Robert Loddenkemper MD FCCP

Former Chief of Department of Pneumology Lungenklinik Heckeshorn Berlin/Germany Professor Emeritus of Charité University Medicine Berlin Past-President of the European Respiratory Society Germany

### Alan D Lopez PhD

University of Melbourne Laureate Professor
Rowden-White Chair of Global Health and Burden of Disease Measurement
Director, Global Burden of Disease Group
Melbourne School of Population and Global Health
University of Melbourne
Former Chief epidemiologist, WHO's Tobacco or Health Program (1992-1996)
Former Head, WHO Program on Substance Abuse (1996-1998)
Australia

#### Professor Dr Johan P Mackenbach

Department of Public Health
Erasmus MC
Rotterdam
The Netherlands

### **Ruth E Malone RN PhD FAAN**

Professor and Chair, Department of Social and Behavioral Sciences Nursing Alumni/Mary Harms Endowed Chair School of Nursing University of California, San Francisco Editor-in-Chief, Tobacco Control USA

### Professor Julian Mamo MD MSc PhD MFPH(UK)

Head, Department Public Health Faculty of Medicine & Surgery University of Malta Malta

#### Jose Maria Martin-Moreno MD PhD

Professor of Preventive Medicine and Public Health University of Valencia Spain

## Bongani M Mayosi DPhil FCP(SA)

Professor and Head
Department of Medicine
Groote Schuur Hospital & University of Cape Town
Cape Town
South Africa

## Wasim Maziak MD PhD

Professor and Chair, Department of Epidemiology Robert Stempel College of Public Health and Social Work Florida International University, Miami, Florida Director, Syrian Center for Tobacco Studies USA

### Jim McCambridge PhD

Senior Lecturer in Behaviour Change Faculty of Public Health & Policy London School of Hygiene & Tropical Medicine United Kingdom

#### **Professor Martin McKee CBE**

European Centre on Health of Societies in Transition London School of Hygiene and Tropical Medicine United Kingdom

### **Robert McMillen PhD**

Associate Professor Social Science Research Center, Coordinator of the Tobacco Control Unit Department of Psychology American Academy of Pediatrics, Julius B. Richmond Center of Excellence USA

## Raúl Mejía MD

Investigador Titular Centro de Estudios de Estado y Sociedad Buenos Aires Argentina

#### John Middleton

Vice President Faculty of Public Health United Kingdom

### José Pereira Miguel MD PhD

Full Professor of Preventive Medicine and Public Health Faculty of Medicine University of Lisbon Portugal

## **Rob Moodie AM MBBS MPH FAFPHM FRACGP DTMH**

Professor of Public Health University of Melbourne Australia

### Michael Moore

CEO Public Health Association of Australia
Vice President/President Elect World Federation of Public Health Associations
Australia

## John F Murray MD FRCP

Professor Emeritus of Medicine University of California San Francisco USA

#### Rima Nakkash DrPH MPH

Assistant professor

Health Promotion and Community Health Department (WHO Collaborating Center on Health
Promotion and Behavioural sciences)

Coordinator of the AUB Tobacco Control Research Group

American University of Beirut
Lebanon

## **Professor Dr Manfred Neuberger MD**

Professor emeritus Medical University of Vienna Austria

### **Thomas E Novotny MD MPH**

Professor of Global Health
Graduate School of Public Health
San Diego State University
Former Assistant Surgeon General, US Public Health Service
Former US Representative to the WHO Executive Board
USA

# Professor Ian Olver AM MBBS MD PhD FRACP FAChPM AFRACMA

Medical Oncologist Chief Executive Officer, Cancer Council Australia Australia

### Fred Paccaud MD MSc

Institute for Social and Preventive Medicine University Hospital Center (CHUV) Lausanne Switzerland

## **Alexander A Padilla**

President and CEO, PHILHEALTH
Philippine Health Insurance Corporation
The Philippines

## **Cheryl L Perry PhD**

Professor and Regional Dean
The Rockwell Distinguished Chair in Society and Health
University of Texas School of Public Health
Austin Regional Campus
USA

### Michael Pertschuk

Former Chairman, US Federal Trade Commission Former Co-Director, The Advocacy Institute USA

#### John P Pierce PhD

Distinguished Professor in Cancer Prevention
Department of Family and Preventive Medicine
Director, Population Sciences Division
Moores Cancer Center
University of California, San Diego
USA

### **Professor Allyson Pollock**

Prof Public Health Research and Policy Queen Mary, University of London United Kingdom

## Dr Martina Pötschke-Langer MD MA

Head of Unit Cancer Prevention and of WHO Collaborating Centre for Tobacco Control German Cancer Research Center (DKFZ) Heidelberg Germany

#### **Robert N Proctor PhD**

Professor of the History of Science and Professor, by courtesy, of Pulmonary and Critical Care Medicine Stanford University USA

#### **Professor Pekka Puska**

Ex Director General
Terveyden ja hyvinvoinnin laitos – National Institute for Health and Welfare (THL)
Helsinki
Finland

## K Srinath Reddy MD DM MSc DSc (Honoris Causa) DLitt (Honoris Causa)

President, Public Health Foundation of India President, World Heart Federation India

#### Dr Maria de Fátima Reis

Professor of Environmental Health Faculty of Medicine University of Lisbon. Portugal

### James Repace MSc

Repace Associates, Inc.
Secondhand Smoke Consultants
USA

## Professor Juan M Rey-Pino

Associate Professor
Department of Marketing Research and Management
University of Granada
Spain

#### **Professor Walter Ricciardi**

Director of the Department of Public Health
Deputy Head (2010 - 2014) of the Faculty of Medicine "A. Gemelli"
Catholic University of the Sacred Heart
Rome
Italy

# Ms Bungon Ritthiphakdee

Director
Southeast Asia Tobacco Control Alliance (SEATCA)
Thailand

#### **Dr Harry Rutter**

London School of Hygiene and Tropical Medicine United Kingdom

## Maria Victoria Salgado MD

Family Medicine Resident Hospital Italiano de Buenos Aires Argentina

## Dr Yussuf Saloojee

Executive Director National Council Against Smoking South Africa

### **Professor Raul H Sansores MD**

Departamento de Investigacion en Tabaquismo Director, Smoking Cessation Program National Institute of Respiratory Diseases Mexico

### Linda Sarna PhD RN FAAN

Professor and Lulu Wolf Hassenplug Endowed Chair Immediate Past Chair, Academic Senate UCLA School of Nursing Los Angeles, California USA

### Dean E Schraufnagel MD

Professor
Pulmonary, Critical Care, Sleep, and Allergy
Depart of Medicine M/C 719
University of Illinois at Chicago
USA

### Dr Dr hc Rolf Schulte-Hermann

Professor of Toxicology EUROPEAN Registered Toxicologist (ERT) Former Director, Institute of Cancer Research, Head, Unit Chemical Safety and Cancer Prevention Medical University of Vienna Austria

### Alan Shihadeh

Professor, Department of Mechanical Engineering
Principal Investigator, Aerosol Research Lab
American University of Beirut
Beirut
Lebanon
Project Director
Center for the Study of Tobacco Products
Virginia Commonwealth University
Richmond, Virginia
USA

## **Associate Prof Freddy Sitas DPhil**

Director, Cancer Research Division Cancer Council NSW Australia

## **Bernard W Stewart PhD FRACI DipLaw**

Professor
School of Women's and Children's Health, UNSW and Head,
Cancer Control Program
South East Sydney Public Health Unit
Australia

#### Maurice G Swanson

Chief Executive
National Heart Foundation of Australia, WA Division
Deputy Chair,
Cancer Council Australia and National Heart Foundation of Australia Tobacco Issues Committee
Australia

#### Dr Naveen Thacker MD

President Elect, Asia Pacific Pediatric Association India

### **Associate Professor Samantha Thomas**

Principal Research Fellow Public Health School of Health and Society Faculty of Social Sciences University of Wollongong Australia

## **TH Tulchinsky MD MPH**

Emeritus Professor, Braun School Public Health, Hebrew University-Hadassah, Ein Karem, Jerusalem, Israel
Deputy Editor, Public Health Reviews, EHESP, Paris
Israel

#### Silvana Rubano B Turci

Centro de Estudos sobre Tabaco e Saúde da Escola Nacional de Saúde Pública da Fundação Oswaldo Cruz (CETAB/ENSP/Fiocruz)
Brazil

# Professor Prakit Vathesatogkit MD ABIM FRCP (T) FRCP

Secretary-General, ASH Thailand Thailand

#### **Russell Viner**

17.1

Professor of Adolescent Health UCL Institute of Child Health United Kingdom

## Vasiliy V Vlassov MD

President,
Russian Society for Evidence Based Medicine
Russian Federation

## **Professor Melanie Wakefield PhD FASSA**

Director and NHMRC Principal Research Fellow Centre for Behavioural Research in Cancer Cancer Council Victoria Melbourne Australia

## **Professor Kenneth D Ward PhD**

Professor and Director, Division of Social and Behavioral Sciences School of Public Health The University of Memphis USA

### **Professor Alan White**

Centre for Men's Health, Institute for Health & Wellbeing Leeds Metropolitan University United Kingdom

## Martin White MD FFPH

Professor of Public Health, institute of Health & Society, Newcastle University Director, Fuse - UKCRC Centre for Translational Research in Public Health United Kingdom

### **Prof Friedrich J Wiebel**

formerly Institute of Toxicology German Research Center for Environmental Health, Neuherberg/Muenchen Germany

# **James Wiley MD**

Founder and chairman Focus Pediatrics, Mobile, AL USA

## Jonathan P. Winickoff MD, MPH

Director of Translational Research
American Academy of Pediatrics Julius B. Richmond Center
Associate Professor of Pediatrics
Harvard Medical School
USA

### **Dr Ingrid Wolfe**

Child Public Health Research Fellow London School of Hygiene and Tropical Medicine United Kingdom

#### Dr Salim Yusuf DPhil FRCPC FRSC OC

Professor of Medicine, McMaster University
Executive Director, Population Health Research Institute
McMaster University, Hamilton Health Sciences
Vice President Research, Hamilton Health Sciences
Heart and Stroke Foundation/Marion W. Burke Chair in Cardiovascular Disease
President Elect, World Heart Federation
Canada

<sup>&</sup>lt;sup>1</sup>http://www.who.int/entitv/tobacco/communications/statements/eletronic\_cigarettes/en/index.html

<sup>&</sup>lt;sup>2</sup> http://nicotinepolicy.net/n-s-p/1751-statement-who-052014

<sup>&</sup>lt;sup>3</sup> Peeters S, Gilmore AB. Understanding the emergence of the tobacco industry's use of the term tobacco harm reduction in order to inform public health policy. Tob Control. 2014 Jan 22. doi: 10.1136/tobaccocontrol-2013-051502.

<sup>4</sup> http://www.cbsnews.com/news/tobacco-companies-bet-on-electronic-cigarettes/

http://blog.euromonitor.com/2012/11/e-cigarettes-a-us2-billion-globai-industry-who-should-be-worried.html
 http://www.who.int/fctc/guidelines/article\_5\_3.pdf?ua=1

<sup>&</sup>lt;sup>7</sup> http://www.usatoday.com/story/news/nation/2012/11/27/judge-orders-tobacco-ads-declaring-deception/1730211/

<sup>&</sup>lt;sup>8</sup> Bialous SA, Sarma L.Electronic cigarettes and smoking cessation: a quandary? (letter) Lancet. 2014 Feb 1;383(9915):407-8. doi: 10.1016/S0140-6736(14)60143-4.

<sup>&</sup>lt;sup>9</sup> de Andrade M, Hastings G, Angus K. Promotion of electronic cigarettes: tobacco marketing reinvented? BMJ. 2013 Dec 21;347:f7473. doi: 10.1136/bmj.f7473.

<sup>&</sup>lt;sup>10</sup> McCarthy M. E-cigarette companies target youth, US congressional study finds. BMJ. 2014 Apr 22;348:g2871. doi: 10.1136/bmj.g2871.

<sup>&</sup>lt;sup>11</sup> Legacy. Vaporized: E-Cigarettes, Advertising, And Youth. May 2014 http://legacyforhealth.org/content/download/4542/63436/version/1/file/LEG-Vaporized-E-cig\_Report-May2014.pdf

<sup>&</sup>lt;sup>12</sup> Jennifer C. Duke, Youn O. Lee, et al. Exposure to Electronic Cigarette Television Advertisements Among Youth and Young Adults. Pediatrics. Published online June 2, 2014. (doi: 10.1542/peds.2014-0269)

<sup>&</sup>lt;sup>13</sup> Dutra LM, Glantz SA. Electronic Cigarettes and Conventional Cigarette Use Among US Adolescents: A Cross-sectional Study. JAMA Pediatr. 2014 Mar 6. doi: 10.1001/jamapediatrics.2013.5488. [Epub ahead of print]

<sup>&</sup>lt;sup>14</sup> Centers for Disease Control and Prevention (CDC). Notes from the field: electronic cigarette use among middle and high school students - United States, 2011-2012.MMWR Morb Mortal Wkiy Rep. 2013 Sep 6;62(35):729-30.

<sup>&</sup>lt;sup>15</sup> Lee S, Grana RA, Glantz SA. Electronic cigarette use among Korean adolescents: a cross-sectional study of market penetration, dual use, and relationship to quit attempts and former smoking.

<sup>16</sup> http://www.realparentsrealanswers.com/what-you-need-to-know-about-e-cigarettes-infographic/

<sup>&</sup>lt;sup>17</sup> Grana RA, Ling PM. Smoking revolution": a content analysis of electronic cigarette retail websites. Am J Prev Med. 2014 Apr;46(4):395-403. doi: 10.1016/j.amepre.2013.12.010.

<sup>&</sup>lt;sup>18</sup> Carr ER. E-cigarettes: facts, perceptions, and marketing messages. Clin J Oncol Nurs. 2014 Feb;18(1):112-6. doi: 10.1188/14.CJON.112-116.

<sup>&</sup>lt;sup>19</sup> Rooke C, Amos A. News media representations of electronic cigarettes: an analysis of newspaper coverage in the UK and Scotland [published online ahead of print July 24, 2013]. Tob Control. doi:10.1136/tobaccocontrol-2013—051043

<sup>&</sup>lt;sup>20</sup> Grana R, Benowitz N, Glantz SA.Circulation. E-cigarettes: a scientific review. Circulation 2014 May 13;129(19):1972-86. doi: 10.1161/CIRCULATIONAHA.114.007667.

<sup>21</sup> ibid.

<sup>&</sup>lt;sup>22</sup> Pisinger C, Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine Tob Res. 2007 Jun;9(6):631-46.

<sup>&</sup>lt;sup>23</sup> Adkison SE, O'Connor RJ, Bansal-Travers M, Hyland A, Borland R, Yong HH, Cummings KM, McNeill A, Thrasher JF, Hammond D, Fong GT. Electronic nicotine delivery systems: international tobacco control four-country survey. Am J Prev Med. 2013 Mar; 44(3):207-15.

<sup>&</sup>lt;sup>24</sup> Grana R, Popova L, Ling P. A longitudinal analysis of electronic cigarette use and smoking cessation [published online ahead of print March 24, 2014]. JAMA Int Med. doi:10.1001/jamainternmed.2014.187.

<sup>&</sup>lt;sup>25</sup> Vickerman KA, Carpenter KM, Altman T, Nash CM, Zbikowski SM. Use of electronic cigarettes among state tobacco cessation quitline callers. Nicotine Tob Res. 2013;15:1787–1791.

Popova L, Ling PM. Alternative tobacco product use and smoking cessation: a national study. Am J Public Health. 2013:103:923–930.

<sup>&</sup>lt;sup>27</sup> Choi K, Forster JL. Response to Letter to the Editor Regarding "Beliefs and Experimentation with Electronic Cigarettes: A Prospective Analysis Among Young Adults." Am J Prev Med

<sup>28</sup> See reference #20.

Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial.

Lancet. 2013 Nov 16;382(9905):1629-37. doi: 10.1016/S0140-6736(13)61842-5. Epub 2013 Sep 9.

<sup>&</sup>lt;sup>30</sup> Brown J, Beard E, Kotz D, Michie S, West R. Real-world effectiveness of e-cigarettes when used to aid smoking cessation: a cross-sectional population study.

Addiction. 2014 May 20. doi: 10.1111/add.12623. [Epub ahead of print]

<sup>31</sup> Ibid

<sup>&</sup>lt;sup>32</sup> Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rostk-Dulewska C, Havel C. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23:133–139.

kim HJ, Shin HS. Determination of tobacco-specific nitrosamines in replacement liquids of electronic cigarettes by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2013;1291:48–55.

Farsalinos KE, Romagna G, Allifranchini E, Ripamonti E, Bocchietto E, Todeschi S, Tsiapras D, Kyrzopoulos S, Voudris V. Comparison of the cytotoxic potential of cigarette smoke and electronic cigarette vapour extract on cultured myocardial cells. Int J Environ Res Public Health. 2013;10:5146–5162.

<sup>&</sup>lt;sup>35</sup> Flouris AD, Chorti MS, Poulianiti KP, Jamurtas AZ, Kostikas K, Tzatzarakis MN, Wallace Hayes A, Tsatsakis AM, Koutedakis Y. Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. Inhal Toxicol. 2013;25:91–101.

Nicotine Tob Res. 2013 Feb: 15(2):501-8.

<sup>39</sup> Williams M, Villarreal A, Bozhiiov K, Lin S, Talbot P. Metal and silicate particles including nanoparticles are

present in electronic cigarette cartomizer fluid and aerosol. PLoS One. 2013; 8(3):e57987.

<sup>40</sup> Laino T, Tuma C, Moor P, Martin E, Stoiz S, Curioni A. Mechanisms of propylene glycol and triacetin pyrolysis. J Phys Chem A. 2012 May 10; 116(18):4602-9.

<sup>41</sup> U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.

42 http://www.nu-mark.com/MarkTen\_Product\_Information\_Guide.pdf

<sup>&</sup>lt;sup>36</sup> Czogala J, Goniewicz ML, Fideius B, Zielinska-Danch W, Travers MJ, Sobczak A. Secondhand exposure to vapors from electronic cigarettes [published online ahead of print December 11, 2013]. Nicotine Tob Res. doi: 10.1093/ntr/ntt203.

<sup>&</sup>lt;sup>37</sup> Zhang Y, Sumner W, Chen DR. In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns.

<sup>&</sup>lt;sup>38</sup> Schober W, Szendrei K, Matzen W, Osiander-Fuchs H, Heitmann D, Schettgen T, Jorres RA, Fromme H. Use of electronic cigarettes (e-cigarettes) impairs indoor air quality and increases FeNO levels of e-cigarette consumers [published online ahead of print December 6, 2013]. Int J Hyg Environ Health. doi: 10.1016/j.ijheh.2013.11.003.